vs
Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and Navitas Semiconductor Corp (NVTS). Click either name above to swap in a different company.
Navitas Semiconductor Corp is the larger business by last-quarter revenue ($8.6M vs $4.8M, roughly 1.8× MAXCYTE, INC.). On growth, MAXCYTE, INC. posted the faster year-over-year revenue change (-20.9% vs -38.7%). Over the past eight quarters, MAXCYTE, INC.'s revenue compounded faster (-7.4% CAGR vs -35.2%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
Navitas Semiconductor Corp is a leading global semiconductor firm specializing in gallium nitride (GaN) power integrated circuits. Its high-efficiency, compact power solutions serve consumer electronics, electric vehicles, renewable energy, and industrial sectors, with clients spanning North America, Asia, and Europe.
MXCT vs NVTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $8.6M |
| Net Profit | $-9.6M | — |
| Gross Margin | — | 98.6% |
| Operating Margin | -234.5% | -260.6% |
| Net Margin | -200.5% | — |
| Revenue YoY | -20.9% | -38.7% |
| Net Profit YoY | 9.4% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $8.6M | ||
| Q4 25 | $4.8M | $7.3M | ||
| Q3 25 | $4.6M | $10.1M | ||
| Q2 25 | $5.8M | $14.5M | ||
| Q1 25 | $5.7M | $14.0M | ||
| Q4 24 | $6.1M | $18.0M | ||
| Q3 24 | $5.6M | $21.7M | ||
| Q2 24 | $5.0M | $20.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-9.6M | $-31.8M | ||
| Q3 25 | $-12.4M | $-19.2M | ||
| Q2 25 | $-12.4M | $-49.1M | ||
| Q1 25 | $-10.3M | $-16.8M | ||
| Q4 24 | $-10.6M | $-39.9M | ||
| Q3 24 | $-11.6M | $-18.7M | ||
| Q2 24 | $-9.4M | $-22.3M |
| Q1 26 | — | 98.6% | ||
| Q4 25 | — | 38.1% | ||
| Q3 25 | — | 37.9% | ||
| Q2 25 | — | 16.1% | ||
| Q1 25 | — | 37.9% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | — | 39.7% | ||
| Q2 24 | — | 39.0% |
| Q1 26 | — | -260.6% | ||
| Q4 25 | -234.5% | -567.3% | ||
| Q3 25 | -307.4% | -192.0% | ||
| Q2 25 | -244.3% | -149.4% | ||
| Q1 25 | -214.1% | -180.5% | ||
| Q4 24 | -213.1% | -216.9% | ||
| Q3 24 | -250.4% | -133.6% | ||
| Q2 24 | -241.0% | -152.1% |
| Q1 26 | — | — | ||
| Q4 25 | -200.5% | -436.1% | ||
| Q3 25 | -269.7% | -190.2% | ||
| Q2 25 | -212.2% | -338.7% | ||
| Q1 25 | -178.7% | -120.1% | ||
| Q4 24 | -175.0% | -221.7% | ||
| Q3 24 | -205.9% | -86.4% | ||
| Q2 24 | -188.8% | -109.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.14 | ||
| Q3 25 | $-0.12 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.25 | ||
| Q1 25 | — | $-0.09 | ||
| Q4 24 | — | $-0.22 | ||
| Q3 24 | $-0.11 | $-0.10 | ||
| Q2 24 | $-0.09 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $221.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.5M | $420.0M |
| Total Assets | $202.5M | $481.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $221.0M | ||
| Q4 25 | $103.0M | $236.9M | ||
| Q3 25 | $105.7M | $150.6M | ||
| Q2 25 | $126.6M | $161.2M | ||
| Q1 25 | $138.3M | $75.1M | ||
| Q4 24 | $154.5M | $86.7M | ||
| Q3 24 | $153.8M | $98.3M | ||
| Q2 24 | $157.3M | $111.7M |
| Q1 26 | — | $420.0M | ||
| Q4 25 | $171.5M | $443.7M | ||
| Q3 25 | $180.3M | $371.0M | ||
| Q2 25 | $190.7M | $388.9M | ||
| Q1 25 | $199.4M | $341.8M | ||
| Q4 24 | $206.3M | $348.0M | ||
| Q3 24 | $213.3M | $380.8M | ||
| Q2 24 | $221.3M | $388.1M |
| Q1 26 | — | $481.4M | ||
| Q4 25 | $202.5M | $500.5M | ||
| Q3 25 | $213.5M | $430.2M | ||
| Q2 25 | $219.8M | $449.4M | ||
| Q1 25 | $230.0M | $370.8M | ||
| Q4 24 | $239.5M | $390.0M | ||
| Q3 24 | $248.6M | $419.4M | ||
| Q2 24 | $251.5M | $439.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | — |
| Free Cash FlowOCF − Capex | $-2.9M | — |
| FCF MarginFCF / Revenue | -61.0% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-36.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-2.7M | $-8.1M | ||
| Q3 25 | $-7.5M | $-10.0M | ||
| Q2 25 | $-9.9M | $-11.2M | ||
| Q1 25 | $-14.4M | $-13.5M | ||
| Q4 24 | $-7.8M | $-10.2M | ||
| Q3 24 | $-4.4M | $-13.7M | ||
| Q2 24 | $-4.8M | $-15.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-2.9M | $-8.2M | ||
| Q3 25 | $-7.8M | $-10.7M | ||
| Q2 25 | $-10.4M | $-11.9M | ||
| Q1 25 | $-15.1M | $-13.6M | ||
| Q4 24 | $-8.0M | $-10.8M | ||
| Q3 24 | $-4.8M | $-14.3M | ||
| Q2 24 | $-5.1M | $-17.9M |
| Q1 26 | — | — | ||
| Q4 25 | -61.0% | -111.8% | ||
| Q3 25 | -168.5% | -106.1% | ||
| Q2 25 | -179.2% | -82.2% | ||
| Q1 25 | -262.3% | -96.8% | ||
| Q4 24 | -131.6% | -59.8% | ||
| Q3 24 | -85.5% | -65.9% | ||
| Q2 24 | -103.3% | -87.3% |
| Q1 26 | — | — | ||
| Q4 25 | 4.8% | 0.7% | ||
| Q3 25 | 6.5% | 7.0% | ||
| Q2 25 | 10.0% | 4.7% | ||
| Q1 25 | 11.4% | 0.3% | ||
| Q4 24 | 2.4% | 3.1% | ||
| Q3 24 | 7.2% | 2.6% | ||
| Q2 24 | 5.9% | 13.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
NVTS
Segment breakdown not available.
